Lv11
30 积分 2025-06-29 加入
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial
1小时前
已完结
Helicobacter pylori Screening After Acute Myocardial Infarction
3天前
已完结
Research trends on vonoprazan‐based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023
2个月前
已完结
States and hotspots in Helicobacter pylori research from 2002 to 2021: A bibliometric analysis
2个月前
已完结
皖公网安备34019202002308
